Annual Report FY 2024-25
Indegene enjoys a differentiated positioning as a digital-first commercialization and transformation partner to the life sciences industry. This stems from a combination of strong attributes cultivated over the years - deep domain expertise, a technology-first mindset, trusted customer relationships, and an agile operating model. As the industry evolves, we continue to bolster our strengths, infusing AI into our solutions and driving operational excellence to create sustained value for stakeholders.
Deep knowledge and understanding of the end-to-end journey of the drug (from research lab to the market) enables us to organize and interpret scientific and clinical data, navigate a complex regulatory environment, and craft accurate, relevant content for healthcare professionals (HCPs), patients, and payers.
Healthcare domain expertise supports modernization and digitization of life sciences commercialization functions, helping clients to optimize sales and marketing costs, personalize omnichannel customer experiences, and improve outcomes in clinical trials and regulatory submissions
23.8% of our delivery employees possess healthcare- related qualifications and expertise, including MD, MBBS, PhD, BDS, MPharm, and BPharm degrees
Advanced capabilities in AI/ML, Natural Language Processing (NLP), and data analytics, seamlessly embed into every stage of the commercialization journey to enhance effectiveness and efficiency
Robust AI-Led Technology Portfolio
GenAI Workbench is a collaborative environment that contextualizes GenAI for real-world business applications in life sciences and rapidly integrates it across our NEXT platform ecosystem
Comprehensive suite of NEXT-branded proprietary tools and platforms automate workflows, enhance efficiency and quality across R&D, regulatory, medical, and commercialization processes of life sciences companies
Cortex, launched in FY 2024-25, is a fit-for-purpose GenAI platform, empowering life sciences domain experts to build scalable, secure, and adaptable AI solutions
Dedicated team of 600+ individuals work on next- generation digital technologies
We have long-standing relationships with some of the world’s largest and most respected biopharmaceutical companies, including the world’s top 20 by revenue, as well as a growing base of mid-sized pharma, emerging biotech, and medical device organizations
We enjoy high client stickiness and retention as solutions are embedded in client workflows, maximizing outcomes
Our land-and-expand strategy is aimed at broadening the range of solutions/services across clients’ commercialization processes through consulting, up-selling and cross-selling
We have a track record of successful acquisitions, leading to strong synergies – expanded client networks, enhanced solutions, complementary capabilities, access to cutting-edge technologies and large global / multinational talent pools
